This company listing is no longer active
NPRR.F Stock Overview
Engages in the medical devices, pharmaceuticals, and pharma packaging businesses.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Nipro Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥8.50 |
| 52 Week High | JP¥8.50 |
| 52 Week Low | JP¥8.50 |
| Beta | 0.47 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| NPRR.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 1.6% |
| 1Y | n/a | -1.0% | 22.3% |
Return vs Industry: Insufficient data to determine how NPRR.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how NPRR.F performed against the US Market.
Price Volatility
| NPRR.F volatility | |
|---|---|
| NPRR.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NPRR.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NPRR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 35,251 | Yoshihiko Sano | www.nipro.co.jp |
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. The company’s Medical Device business develops, manufactures, and sells various disposable medical products comprising renal, intervention and anesthesiology, injection and infusion, dialysis, cardiopulmonary, diabetic, and cell cultures products; and sells artificial organ-related products, and generic and kit products. Its Pharmaceutical business provides pharmaceutical combination products, including dual chamber bags, pre-filled syringes, and half-type kits; and contract manufacturing services for orally administered drugs, injectables, and external preparations.
Nipro Corporation Fundamentals Summary
| NPRR.F fundamental statistics | |
|---|---|
| Market cap | US$1.24b |
| Earnings (TTM) | US$98.79m |
| Revenue (TTM) | US$3.63b |
12.6x
P/E Ratio0.3x
P/S RatioIs NPRR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NPRR.F income statement (TTM) | |
|---|---|
| Revenue | JP¥494.79b |
| Cost of Revenue | JP¥345.52b |
| Gross Profit | JP¥149.27b |
| Other Expenses | JP¥135.82b |
| Earnings | JP¥13.46b |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 09, 2022
| Earnings per share (EPS) | 82.50 |
| Gross Margin | 30.17% |
| Net Profit Margin | 2.72% |
| Debt/Equity Ratio | 267.8% |
How did NPRR.F perform over the long term?
See historical performance and comparison